[1] A. Laguna, Modern supramolecular gold chemistry: gold-metal interactions and ap- plications. John Wiley and Sons, 2008.
[2] T. Muangnapoh, N. Sano, S.-I. Yusa, N. Viriya-empikul, and T. Charinpanitkul, “Facile strategy for stability control of gold nanoparticles synthesized by aqueous reduction method,” Current Applied Physics, vol. 10, no. 2, pp. 708–714, 2010. doi:https://doi.org/10.1016/j.cap.2009.09.005.
[3] P. Georgiev, A. Bojinova, B. Kostova, D. Momekova, T. Bjornholm, and K. Bal- ashev, “Implementing atomic force microscopy (afm) for studying kinetics of gold nanoparticle’s growth,” Colloids and Surfaces A: Physicochemical and Engineering Aspects, vol. 434, pp. 154–163, 2013.
[4] S. Setua, M. Jaggi, M. M. Yallapu, S. C. Chauhan, A. Danilushkina, H. Lee, I. S. Choi, R. Fakhrullin, L. D. Esposti, A. Tampieri, M. Iafisco, M. Shevtsov, and
G. Multhoff, “Chapter 6 - targeted and theranostic applications for nanotechnolo- gies in medicine,” in Nanotechnologies in Preventive and Regenerative Medicine (V. Uskoković and D. P. Uskoković, eds.), Micro and Nano Technologies, pp. 399– 511, Elsevier, 2018. doi: https://doi.org/10.1016/B978-0-323-48063-5.00006-X.
[5] B. Duncan, C. Kim, and V. M. Rotello, “Gold nanoparticle platforms as drug and biomacromolecule delivery systems,” Journal of Controlled Release, vol. 148, no. 1, pp. 122–127, 2010. 11th European Sumposium on Controlled Drug Delivery. doi: https://doi.org/10.1016/j.jconrel.2010.06.004.
[6] V. P. Torchilin, “Structure and design of polymeric surfactant-based drug delivery systems,” Journal of Controlled Release, vol. 73, no. 2, pp. 137–172, 2001. doi:https://doi.org/10.1016/S0168-3659 (01)00299-1.
[7] O. Veiseh, J. W. Gunn, and M. Zhang, “Design and fabrication of magnetic nanopar- ticles for targeted drug delivery and imaging,” Advanced Drug Delivery Reviews, vol. 62, no. 3, pp. 284–304, 2010. Targeted Delivery Using Inorganic Nanosystem.
doi: https://doi.org/10.1016/j.addr.2009.11.002.
[8] M. A. Dobrovolskaia, P. Aggarwal, J. B. Hall, and S. E. McNeil, “Preclinical studies to understand nanoparticle interaction with the immune system and its potential ef- fects on nanoparticle biodistribution,” MOLECULAR PHARMACEUTICS, vol. 5, pp. 487–495, JUL-AUG 2008. 7th International Symposium on Polymer Therapeu- tics, Ctr Invest Principe Felipe, Valencia, SPAIN, MAY 26-28, 2007. doi: {10.1021/mp800032f}.
[9] S. R. Cummings, A. C. Santora, D. M. Black, and R. G. G. Russell, “History of alendronate,” Bone, vol. 137, 2020. doi: 10.1016/j.bone.2020. 115411
[10] H. J. Möbius, “Memantine: update on the current evidence,” International Journal of Geriatric Psychiatry, vol. 18, no. S1, pp. S47–S54, 2003.
doi: https://doi.org/10.1002/ gps.939.
[11] K. M. Krause, A. W. Serio, T. R. Kane, and L. E. Connolly, “Aminoglycosides: An overview,” Cold Spring Harbor Perspectives in Medicine, vol. 6, no. 6, p. 18, 2016. doi:10.1101/cshperspect.a027029.
[12] L. Chronopoulou, E. G. Di Domenico, F. Ascenzioni, and C. Palocci, “Positively charged biopolymeric nanoparticles for the inhibition of Pseudomonas aeruginosa biofilms,” JOURNAL OF NANOPARTICLE RESEARCH, vol. 18, OCT 13 2016. doi:{10.1007/s11051-016-3611-y}.
[13] K. E. Ensrud and C. J. Crandall, “Osteoporosis,” Annals of Internal Medicine, vol. 167, no. 3, pp. ITC17–ITC32, 2017. PMID: 28761958.
doi:10.7326/AITC201708010.
[14] A. P. Nesterova, E. A. Klimov, M. Zharkova, S. Sozin, V. Sobolev, N. V. Ivanikova,
M. Shkrob, and A. Yuryev, “Alzheimer’s disease,” in DISEASE PATHWAYS: AN ATLAS OF HUMAN DISEASE SIGNALING PATHWAYS, pp. 221–233, 2020.
[15] B. Schnapf and P. Farrell, “Cystic Fibrosis,” in METABOLIC DISEASES: FOUN- DATIONS OF CLINICAL MANAGEMENT, GENETICS, AND PATHOLOGY, 2ND EDITION (GilbertBarness, E and Barness, LA and Farrell, PM, ed.), pp. 511– 541, 2017. doi:{10.3233/978-1-61499-718-4-511}.
[16] M. Ayad, H. Abdellatef, M. Hosny, and N. Kabil, “Aggregation of gold nanoparticles for spectrophotometric determination of bisoprolol hemifumarate, buspirone hcl and doxazosin mesylate,” Nano Biomedicine and Engineering, vol. 11, 01 2019. doi:10.5101/nbe.v11i1.p1-10.
[17] X. T. Zheng, W. L. Goh, P. Yeow, D. P. Lane, F. J. Ghadessy, and Y. N. Tan, “Ultrasensitive dynamic light scattering based nanobiosensor for rapid anticancer drug screening,” Sensors and Actuators B: Chemical, vol. 279, pp. 79–86, 2019.
[18] G. Ananchenko, J. Novakovic, and A. Tikhomirova, “Chapter one - alendronate sodium,” in Profiles of Drug Substances, Excipients, and Related Methodology (H. G. Brittain, ed.), vol. 38 of Profiles of Drug Substances, Excipients and Related Method- ology, pp. 1–33, Academic Press, 2013. doi:https://doi.org/10.1016/B978-0-12-407691-4.00001-0.
[19] A. K. Dash, “Tobramycin,” vol. 24 of Analytical Profiles of Drug Substances and Excipients, pp. 579–613, Academic Press, 1996. doi: https://doi.org/10. 1016/S0099-5428(08)60703-0.
[20] P. Prapatpong, T. Techa-In, W. Padungpuak, S. Buranaphalin, and L. Suntorn- suk, “HPLC-Fluorescent Analysis of Memantine: An Investigation on Fluorescent Derivative Formation,” JOURNAL OF CHEMISTRY, vol. 2015, 2015. doi: {10.1155/2015/672183}.
[21] K. Lata, K. Arvind, N. Laxmana, and S. Rajan, “Gold nanoparticles: preparation, characterization and its stability in buffer,” A Journal of Nanotechnology and Its Applications, vol. 17, no. 1, pp. 1–10, 2014. https://www.researchgate.net/publication/ 274195747.
[22] X. Liu, M. Atwater, J. Wang, and Q. Huo, “Extinction coefficient of gold nanoparticles with different sizes and different capping ligands,” Colloids and Surfaces B: Biointerfaces, vol. 58, no. 1, pp. 3–7, 2007. Supramolecular Chemistry Applied to Interfaces. doi: https://doi.org/10.1016/j.colsurfb.2006.08.005.
[23] H. Tyagi, A. Kushwaha, A. Kumar, and M. Aslam, “A facile ph controlled citrate- based reduction method for gold nanoparticle synthesis at room temperature,” Nanoscale research letters, vol. 11, no. 1, pp. 1–11, 2016. doi:https: //doi.org/10.1186/s11671-016-1576-5.